"Second Opinion" with Christina Farr, Ash Zenooz MD & Luba Greenwood JD
Christina Farr, Luba Greenwood, Ash Zenooz
39 episodes
4 months ago
If you’re obsessed with health-tech and life sciences, this is the podcast for you. Second Opinion doesn't hold back. Join Luba Greenwood, Christina Farr, and Ash Zenooz as they bring influential entrepreneurs, experts and investors into the ring for candid conversations at the frontlines of healthcare and digital health every week. Healthcare, health-tech and life sciences in particular, is hard to navigate even for the most seasoned professionals. Unpacking the latest technological, medical, and scientific advances, regulatory hurdles, global economic shifts, and industry and investment trends, requires a powerful combination of hosts like us.
We aim to sift through the noise and help you navigate what’s really going on in healthcare and how to spot the next win. This season, we’re tackling meaty topics like biosecurity, the latest in telemedicine, why patient acquisition is so hard, and the pros and cons of VC versus private equity in funding startups in the healthtech space.
Christina Farr is a former investigative journalist for CNBC — during her tenure as a reporter, she broke some big health-tech stories ranging from Amazon’s first moves into the sector to Apple’s secretive acquisitions. Now Christina is the author at Second Opinion, a newsletter with +20K subscribers. Joining Christina are co-hosts Luba Greenwood, JD — former CEO of Kojin Therapeutics and managing partner at Dana-Farber Cancer Institute — and Ash Zenooz, MD — former CEO of Commure and partner at Luxeda Holdings.
Second Opinion is is a part of the Turpentine podcast network. Learn more: turpentine.co
All content for "Second Opinion" with Christina Farr, Ash Zenooz MD & Luba Greenwood JD is the property of Christina Farr, Luba Greenwood, Ash Zenooz and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
If you’re obsessed with health-tech and life sciences, this is the podcast for you. Second Opinion doesn't hold back. Join Luba Greenwood, Christina Farr, and Ash Zenooz as they bring influential entrepreneurs, experts and investors into the ring for candid conversations at the frontlines of healthcare and digital health every week. Healthcare, health-tech and life sciences in particular, is hard to navigate even for the most seasoned professionals. Unpacking the latest technological, medical, and scientific advances, regulatory hurdles, global economic shifts, and industry and investment trends, requires a powerful combination of hosts like us.
We aim to sift through the noise and help you navigate what’s really going on in healthcare and how to spot the next win. This season, we’re tackling meaty topics like biosecurity, the latest in telemedicine, why patient acquisition is so hard, and the pros and cons of VC versus private equity in funding startups in the healthtech space.
Christina Farr is a former investigative journalist for CNBC — during her tenure as a reporter, she broke some big health-tech stories ranging from Amazon’s first moves into the sector to Apple’s secretive acquisitions. Now Christina is the author at Second Opinion, a newsletter with +20K subscribers. Joining Christina are co-hosts Luba Greenwood, JD — former CEO of Kojin Therapeutics and managing partner at Dana-Farber Cancer Institute — and Ash Zenooz, MD — former CEO of Commure and partner at Luxeda Holdings.
Second Opinion is is a part of the Turpentine podcast network. Learn more: turpentine.co
Are there better alternatives to Ozempic with Sami Inkinen, CEO of Virta Health
"Second Opinion" with Christina Farr, Ash Zenooz MD & Luba Greenwood JD
43 minutes
8 months ago
Are there better alternatives to Ozempic with Sami Inkinen, CEO of Virta Health
This week on Second Opinion, we're featuring Christina Farr, Ash Zenooz, and Luba Greenwood's conversation with Sami Inkinen, CEO of Virta Health. They discuss the company's mission to reverse type 2 diabetes and obesity through personalized nutrition and intensive telemedicine.
—
📰 Be notified early when Turpentine drops new publication: https://www.turpentine.co/exclusiveaccess
🙏 Help shape our show by taking our quick listener survey at https://bit.ly/TurpentinePulse
—
SPONSOR:
👩⚕️ Hot flashes, insomnia, brain fog? You don't have to accept these as just another part of aging. Midi Health is the virtual care clinic for women navigating midlife hormonal transition, offering FDA-approved medications, supplements and lifestyle coaching - all covered by insurance. Visit https://www.joinmidi.com/ to book your virtual visit today.
—
LINKS:
Virta Health: https://www.virtahealth.com/
PHTI: https://phti.org/
Caroline Pearson on Second Opinion: https://www.youtube.com/watch?v=nbo3T654g6c
—
FOLLOW:
https://www.linkedin.com/in/samiinkinen/
https://www.linkedin.com/in/christinafarr/
https://www.linkedin.com/in/lubagreenwood/
https://www.linkedin.com/in/ashzenooz/
—
HIGHLIGHTS FROM THE EPISODE:
Sami Inkinen is an "accidental healthcare entrepreneur" who founded Virta Health after discovering he was pre-diabetic despite being a world championship triathlete.
Sami's key insight was that "you cannot outrun a bad diet" – excessive processed carbohydrates lead to insulin resistance regardless of exercise level.
Virta Health's mission is to reverse type 2 diabetes and obesity in 1 billion people through nutrition, lifestyle changes, and telemedicine support.
Virta spent five years running clinical trials that demonstrated they could reverse type 2 diabetes and deliver sustained weight loss (13% at one and two years).
They highly individualize treatment plans based on each person's circumstances, whether they're eating from a casino, a 7-Eleven, or McDonald's.
Unlike traditional quarterly doctor visits, Virta provides 2-3 interactions daily, monitoring biomarkers and adjusting in near real-time.
Their approach doesn't rely on willpower – patients eat to satiety, which is key to long-term success.
Patients typically get free access to Virta, with employers or health plans paying because Virta saves them about $600/month per patient.
The Peterson Health Technology Institute found Virta was the only digital diabetes program that actually worked.
Sami believes the ideal obesity treatment combines nutrition (as first-line defense) with GLP-1 drugs when necessary, not an either/or approach.
Virta employs full-time doctors and coaches who form long-term relationships with patients, empowered by software and AI.
The company is focusing on scaling their current services, becoming profitable in 2025, and potentially becoming a public company.
"Second Opinion" with Christina Farr, Ash Zenooz MD & Luba Greenwood JD
If you’re obsessed with health-tech and life sciences, this is the podcast for you. Second Opinion doesn't hold back. Join Luba Greenwood, Christina Farr, and Ash Zenooz as they bring influential entrepreneurs, experts and investors into the ring for candid conversations at the frontlines of healthcare and digital health every week. Healthcare, health-tech and life sciences in particular, is hard to navigate even for the most seasoned professionals. Unpacking the latest technological, medical, and scientific advances, regulatory hurdles, global economic shifts, and industry and investment trends, requires a powerful combination of hosts like us.
We aim to sift through the noise and help you navigate what’s really going on in healthcare and how to spot the next win. This season, we’re tackling meaty topics like biosecurity, the latest in telemedicine, why patient acquisition is so hard, and the pros and cons of VC versus private equity in funding startups in the healthtech space.
Christina Farr is a former investigative journalist for CNBC — during her tenure as a reporter, she broke some big health-tech stories ranging from Amazon’s first moves into the sector to Apple’s secretive acquisitions. Now Christina is the author at Second Opinion, a newsletter with +20K subscribers. Joining Christina are co-hosts Luba Greenwood, JD — former CEO of Kojin Therapeutics and managing partner at Dana-Farber Cancer Institute — and Ash Zenooz, MD — former CEO of Commure and partner at Luxeda Holdings.
Second Opinion is is a part of the Turpentine podcast network. Learn more: turpentine.co